UmbriaExplore our travel guides. Share your stories, tips and questions on Reddit.
Fast movers • Alerts • Momentum
10% OFF with SAVE10
Charts • Watchlists • Multi-broker tools
Built for active traders
Biotech catalyst, news and analysis PDUFA tracker
Biotech catalyst, news and analysis PDUFA tracker
The Phase 2b LUMUS trial failed its primary and secondary endpoints in the overall systemic-lupus population. A prespecified IFNGS-high subgroup gives Alumis a regulatory question worth asking, not a validated Phase 3 path. Meanwhile, the separate psoriasis program still targets an NDA filing in Q4 2026.
Get every Merlintrader report in real time on Telegram: join @merlintraderpub_com.
LUMUS damaged the lupus option but did not erase the Phase 3 psoriasis results. The post-drop case depends on keeping those programs separate while refusing to price the IFNGS-high hypothesis as proven.
The decisive lupus question is whether regulators accept an IFNGS-enriched Phase 3 design, dose and assay strategy. Separately, the psoriasis filing tests whether the validated ONWARD package stays on schedule. Alumis has not supplied exact dates for either event.
Envudeucitinib already has two positive Phase 3 psoriasis trials and supportive 48-week extension data. Alumis still expects a Q4 2026 NDA submission, held $502.3 million of cash and marketable securities at June 30, and guides the current operating plan into Q4 2027. If the psoriasis filing clears review and the IFNGS-high hypothesis wins regulatory support, the post-LUMUS equity value may be assigning too little to the lead asset and platform.
LUMUS failed across the overall population, and the IFNGS-low subgroup moved in the wrong direction on BICLA. A post hoc narrative is not the same as a registrational strategy, even when the subgroup was prespecified. Psoriasis enters a competitive TYK2 market, the company is loss-making, and a future lupus Phase 3 would consume capital before its biomarker thesis is proven.
Two Samsara funds associated with director Srinivas Akkaraju bought 546,581 shares at a weighted average of $10.6271 and sold 96,131 at $10.5484 on September 8, 2026. The filing notes that the matched trades create short-swing profit liability under Section 16(b).
The short answer is that the broad lupus thesis did not survive, while the psoriasis filing path did. LUMUS was designed to test whether three envudeucitinib regimens could improve BICLA at Week 48 in a broad moderate-to-severe, autoantibody-positive systemic-lupus population receiving background standard care. All three missed. The result removes the most ambitious interpretation of the program: one oral TYK2 medicine working across an unselected SLE population.
The surviving lupus thesis is narrower. Alumis measured a four-gene type-I interferon signature at baseline and prespecified high and low subgroups. Patients classified as IFNGS-high showed stronger responses, particularly at 40 mg twice daily. Patients classified as IFNGS-low did not. A regulator could regard that as a biologically coherent enrichment strategy, or could regard it as insufficient to rescue a failed trial without further dose, assay and reproducibility work. The company intends to seek FDA and EMA feedback before defining a Phase 3.
The psoriasis evidence stands on a different foundation: two completed randomized Phase 3 trials met their primary and secondary endpoints, followed by supportive longer-duration data. The equity therefore is no longer a single all-or-nothing lupus event. It is a late-stage psoriasis program plus a damaged but not extinguished lupus option, a CNS-penetrant TYK2 candidate and a cash balance that must fund the next proof points.
Alumis presented additional Phase 3 ONWARD analyses of investigational envudeucitinib at Fall Clinical, covering scalp disease, itch and quality of life. More than 80% maintained clear or almost-clear scalp skin at Week 48 and more than 70% maintained a DLQI score of 0 or 1. The ONWARD3 continuous-treatment analysis uses non-responder imputation in 773 patients, rather than the full 1,509-person extension population. The company reported no new long-term safety signals and reiterated a Q4 2026 NDA submission target. These analyses do not establish superiority to other medicines or reverse the separate failed LUMUS lupus readout.
Two Samsara funds associated with director Srinivas Akkaraju bought 546,581 shares at a weighted average of $10.6271 and sold 96,131 at $10.5484 on September 8, 2026. The filing notes that the matched trades create short-swing profit liability under Section 16(b).
The schedule announces participation; it does not establish new clinical results or revised guidance.
None of the three envudeucitinib regimens produced a statistically significant BICLA improvement over placebo at Week 48. Alumis also states that the secondary endpoints were not met in the overall population.
In IFNGS-high patients, BICLA was 28.6% on placebo and 52.6% on 40 mg twice daily. The subgroup was prespecified, but it remains part of a failed trial and requires regulatory agreement and prospective replication.
The full deep dive has the answer’s building blocks: cash, dilution, catalysts and risks, every figure sourced.
Free. No signup. You decide, we don’t recommend.
The NDA is submitted and accepted on schedule, the safety package remains clean, and FDA/EMA feedback supports a focused IFNGS-high Phase 3 with a manageable assay and dose.
The NDA proceeds, but regulators demand more exploratory work before a lupus Phase 3. Alumis preserves cash by treating SLE as a lower-priority option.
The filing slips or encounters safety, CMC or labeling friction; the lupus strategy lacks regulatory support; burn and financing needs rise before commercial validation.
These are analytical scenarios, not price targets or probability estimates. The evidence needed to distinguish them is observable: filing status, regulator feedback, detailed safety data, capital allocation and the design of any new study.
Alumis is best understood as a company with one drug and two separate evidence packages: a positive Phase 3 programme in psoriasis that is heading for a filing, and a Phase 2b in lupus that missed its primary endpoint but produced a subgroup signal. Five things would show that reading to be wrong, and each is checkable against a filing, a regulator record or a company release.
None of these is a prediction. They are the observations that would make the rest of this page wrong, listed so that a reader can check them rather than take the reading on trust.
The short answer is that the broad lupus thesis did not survive, while the psoriasis filing path did. LUMUS was designed to test whether three envudeucitinib regimens could improve BICLA at Week 48 in a broad moderate-to-severe, autoantibody-positive systemic-lupus population receiving background standard care. All three missed. The result removes the most ambitious interpretation of the program: one oral TYK2 medicine working across an unselected SLE population.
The surviving lupus thesis is narrower. Alumis measured a four-gene type-I interferon signature at baseline and prespecified high and low subgroups. Patients classified as IFNGS-high showed stronger responses, particularly at 40 mg twice daily. Patients classified as IFNGS-low did not. A regulator could regard that as a biologically coherent enrichment strategy, or could regard it as insufficient to rescue a failed trial without further dose, assay and reproducibility work. The company intends to seek FDA and EMA feedback before defining a Phase 3.
The psoriasis evidence stands on a different foundation: two completed randomized Phase 3 trials met their primary and secondary endpoints, followed by supportive longer-duration data. The equity therefore is no longer a single all-or-nothing lupus event. It is a late-stage psoriasis program plus a damaged but not extinguished lupus option, a CNS-penetrant TYK2 candidate and a cash balance that must fund the next proof points.
Merlintrader classification: ALMS is a late-stage immunology biotech with a validated psoriasis efficacy package and an unvalidated biomarker-enriched lupus strategy. Those two claims carry different evidentiary weights and stand on separate footing.
Alumis develops targeted therapies for immune-mediated diseases. Its core scientific bet is that selective inhibition of tyrosine kinase 2, or TYK2, can modulate cytokine pathways implicated in inflammatory and autoimmune disease without directly inhibiting JAK1, JAK2 or JAK3. Envudeucitinib, formerly ESK-001, is an oral allosteric TYK2 inhibitor and the company’s lead asset. A-005 applies the same target to a brain-penetrant molecule intended for neuroinflammatory disease.
ONWARD1 and ONWARD2 were positive Phase 3 trials. ONWARD3 supplies longer-term data. Alumis targets a Q4 2026 U.S. NDA submission.
LUMUS was negative overall. A prespecified IFNGS-high subgroup supports regulatory discussion, not a confirmed pivotal design.
Phase 1 target-engagement and CNS-penetration observations support a planned Phase 2 biomarker trial in the first half of 2027.
The current company also reflects its 2025 merger with ACELYRIN. One acquired program, lonigutamab, was placed into a strategic-alternatives process in 2026 and its associated acquired in-process R&D asset was impaired by $41.8 million in Q2. That history matters because it shows that the balance sheet and share count fund a broader organization than envudeucitinib alone, while management is actively narrowing capital allocation.
Alumis reports that LUMUS Part A (NCT05966480) enrolled 408 adults with moderately to severely active, autoantibody-positive SLE on background standard-of-care therapy. The topline efficacy table lists denominators of 101 for placebo, 102 for envudeucitinib 40 mg twice daily, 99 for 20 mg twice daily and 103 for 20 mg once daily—405 patients in total. The sponsor materials do not reconcile the three-patient difference in that table. Treatment lasted 48 weeks before an open-label extension.
The primary endpoint was BICLA response at Week 48. BICLA requires improvement in disease activity without clinically meaningful worsening in other components and without prohibited treatment changes. Key secondary measures included SRI-4, CLASI-50, low lupus disease activity state, corticosteroid reduction, active-joint reduction and flares. The trial therefore tested broad clinical activity rather than a laboratory surrogate alone.
The interferon-gene-signature analysis was not invented after topline failure. Baseline blood RNA sequencing classified participants using a four-gene signature—HERC5, IFI27, IFIT1 and RSAD2—and the high/low analysis was prespecified. However, prespecification does not automatically control every multiplicity issue or replace a successful primary endpoint. The exact assay, cutoff, missing-data handling and regulatory acceptability must be locked before a pivotal study.
Design boundary: LUMUS can generate a credible enriched-population hypothesis because IFNGS was measured at baseline and prespecified. It cannot by itself establish that an IFNGS-high Phase 3 will succeed or that the observed subgroup effect is sufficient for registration.
| Week-48 endpoint | Placebo | 40 mg BID | 20 mg BID | 20 mg QD |
|---|---|---|---|---|
| BICLA response | 35.7% | 41.0% | 42.2% | 40.0% |
| Adjusted difference vs. placebo | — | +6.2 points | +6.9 points | +4.7 points |
| Two-sided p-value | — | 0.3740 | 0.3455 | 0.5018 |
| SRI-4 response | 40.4% | 52.7% | 52.1% | 60.9% |
| SRI-4 nominal p-value | — | 0.0417 | 0.0909 | 0.0028 |
The BICLA confidence intervals for each treatment difference crossed zero and none approached statistical significance. That is the decisive overall-population result. The SRI-4 table contains nominal p-values below 0.05 for two regimens, but Alumis explicitly states that the trial did not achieve its secondary endpoints in the overall population. Those nominal values do not count as successful secondary endpoints, because the prespecified testing hierarchy and multiplicity rules govern formal success.
Alumis attributes the weak overall separation partly to an IFNGS-low proportion of about 40%, higher than the roughly 30% it expected, and to a high placebo response in that group. This may explain the outcome, but explanation and proof are different. Randomization exposed the drug to the population the protocol enrolled; an unfavorable mix is still part of the trial result.
| Prespecified subgroup | Placebo | 40 mg BID | 20 mg BID | 20 mg QD |
|---|---|---|---|---|
| IFNGS-high BICLA (n=63 / 60 / 62 / 64) | 28.6% | 52.6% | 49.5% | 40.7% |
| Adjusted BICLA difference | — | +24.0 points | +21.3 points | +11.6 points |
| IFNGS-high SRI-4 | 33.1% | 60.9% | 57.8% | 67.7% |
| IFNGS-low BICLA (n=38 / 42 / 37 / 39) | 47.5% | 24.4% | 30.0% | 39.0% |
The high-signature BICLA pattern is the strongest argument for continuing in SLE: separation increased with dose, several secondary measures moved in the same direction, and pharmacodynamic data showed the greatest type-I interferon-pathway inhibition at the highest dose. It is also biologically aligned with the central role of interferon signaling in a substantial subset of lupus patients.
The low-signature result is not a neutral footnote. Placebo BICLA reached 47.5%, while every active arm was lower. Small subgroup sizes create wide uncertainty and the pattern does not prove harm, but it means the overall miss is not explained merely by dilution from nonresponders. The Phase 3 decision must address whether enrichment is scientifically and operationally robust, whether 40 mg twice daily is acceptable for chronic use, and whether the commercial assay can reproduce the research classification.
Evidence rule: the IFNGS-high subgroup is hypothesis-strengthening because it was prespecified, dose-coherent on BICLA and mechanistically plausible. It remains unconfirmed because the parent trial failed and no independent prospective study has replicated the selection strategy.
Alumis reports that envudeucitinib was generally well tolerated with no new safety signals. Incidences of treatment-emergent adverse events, Grade 3 or higher events, drug-related events, discontinuations, serious adverse events, serious infections, and embolic or thrombotic events were lower on active treatment than placebo. No major adverse cardiovascular events, extended MACE or malignancies were reported in any arm.
Those statements are useful but sponsor-reported and topline. The release and deck do not provide complete event counts, exposure-adjusted rates, laboratory abnormalities or a detailed dose-by-dose table. The 40 mg twice-daily regimen is particularly important because it delivered the clearest subgroup signal and the most target engagement. A Phase 3 dose choice requires the full safety dataset, not only the directional summary.
The broader TYK2 class still carries clinical considerations. The current U.S. label for deucravacitinib, an approved TYK2 comparator, includes warnings and precautions covering serious infections, tuberculosis screening, malignancy, muscle enzyme elevations, liver enzyme monitoring in known or suspected liver disease, immunizations and uncertainty about whether TYK2 inhibition may share some adverse-reaction associations seen with JAK inhibition. That label does not define envudeucitinib’s safety, but it shows the regulatory benchmark for chronic TYK2 therapy.
ONWARD1 and ONWARD2 were randomized Phase 3 trials in moderate-to-severe plaque psoriasis. Alumis reported that both met all primary and secondary efficacy endpoints. At Week 16, the average across the two studies was 74% for PASI 75 and 59% for static Physician’s Global Assessment 0/1. The detailed Week-24 results were PASI 90 of 68.0% in ONWARD1 and 62.1% in ONWARD2, with PASI 100 of 41.0% and 39.5%, respectively.
ONWARD3 follows patients longer. Among 773 people receiving continuous envudeucitinib for up to 48 weeks, the sponsor reported PASI 90 of 75% and PASI 100 of 54%. In a broader nonresponder-imputation analysis across 890 randomized envudeucitinib patients, the corresponding 48-week rates were 66% and 47%. Both presentations are valid for their stated populations, but they are not interchangeable.
The safety profile across the Phase 3 program was described as consistent with earlier studies, with no new signals in ONWARD3. Complete regulatory review will examine the integrated efficacy, safety, manufacturing and pharmacology package. Positive topline trials make the psoriasis case materially stronger than the lupus case, but they do not guarantee filing acceptance or approval.
Alumis continues to target submission of a U.S. New Drug Application in Q4 2026. A submitted NDA is not the same as an accepted filing, approved label or commercial launch. After submission, investors still need the FDA’s filing decision, review classification, possible information requests, manufacturing readiness, final labeling and any postmarketing commitments.
Commercially, envudeucitinib would enter an established field that includes biologics, oral deucravacitinib and other systemic therapies. The value proposition must therefore combine efficacy depth, durability, safety, convenience, access and net price. Cross-trial PASI comparisons are unreliable because study populations, placebo performance, imputation and timing differ. Head-to-head evidence is more informative where available, and payer positioning may matter as much as headline PASI rates.
The key separation: LUMUS did not invalidate the psoriasis efficacy dataset. It can still affect sentiment, capital allocation and perceptions of the molecule’s breadth, but the FDA will evaluate the psoriasis NDA on the psoriasis package.
| Program | Development status | Next claimed step | Evidence limit |
|---|---|---|---|
| Envudeucitinib — plaque psoriasis | Three Phase 3 studies with positive sponsor-reported data | NDA submission targeted in Q4 2026 | No approval or final label |
| Envudeucitinib — systemic lupus | Phase 2b negative overall; IFNGS-high signal | End-of-Phase-2 discussions; possible enriched Phase 3 | No regulator-endorsed design |
| Envudeucitinib — Sjögren’s / cutaneous lupus | Prioritization discussed before LUMUS | Subject to LUMUS learnings and capital allocation | Timing may change after the miss |
| A-005 — Parkinson’s disease | Phase 1 completed in healthy volunteers | Phase 2 biomarker trial planned for 1H 2027 | No patient efficacy data |
| Lonigutamab | Strategic alternatives under review | No committed development path | $41.8M IPR&D impairment in Q2 2026 |
A-005 is designed to penetrate the central nervous system while inhibiting TYK2. Alumis says Phase 1 showed maximal peripheral target inhibition, CNS penetration and acceptable tolerability in healthy volunteers. A biomarker trial in Parkinson’s disease could show target engagement in patients, but it is not a conventional efficacy trial and should not be valued as proof of disease modification.
Kaken Pharmaceutical holds exclusive rights to develop and commercialize envudeucitinib in Japan for dermatology indications and has options in rheumatology and gastrointestinal diseases. Alumis retained rights outside Japan and in indications not covered or exercised under the agreement.
| Economic item | Disclosed term | Interpretation |
|---|---|---|
| Upfront payment | $20 million | Received under the collaboration |
| Development funding through 2026 | $20 million | Offsets a portion of agreed development work |
| Regulatory and option milestones | Up to $36 million | Conditional, not cash on hand |
| Commercial milestones | Up to ¥15.5 billion | Dependent on future achievements |
| Royalties in Japan | Low double digits into the twenties | Based on future net sales and agreement tiers |
The partnership supplies external validation and reduces some Japan-specific development burden. It does not finance global commercialization, remove U.S. regulatory risk or make the contingent milestone totals equivalent to current cash.
| Reported metric | Q2 / June 30, 2026 | What it means |
|---|---|---|
| Cash and cash equivalents | $63.7M | Immediately liquid balance-sheet cash |
| Current marketable securities | $438.6M | Combined liquidity of $502.3M |
| Q2 collaboration revenue | $1.7M | Not a commercial product-revenue base |
| Q2 R&D expense | $85.3M | Core development spending remains high |
| Q2 G&A expense | $23.4M | Corporate operating cost |
| Q2 IPR&D impairment | $41.8M | Noncash charge tied to lonigutamab |
| Q2 net loss | $142.2M | Includes the impairment |
| First-half operating cash use | $168.6M | Backward-looking burn, not a fixed forecast |
Management says the June 30 liquidity can fund the current operating plan into Q4 2027. That runway is company guidance, not a guarantee. It depends on trial scope, NDA and launch spending, any lupus Phase 3, pipeline prioritization, collaboration receipts and working-capital changes. A post-LUMUS program reset could reduce or increase spending depending on the chosen path.
The balance sheet did not show a funded-debt line at June 30, although lease liabilities were about $4.8 million current and $31.6 million noncurrent. Debt-light does not mean dilution-free: late-stage development and commercialization can require more capital before product cash flows become material.
USD millions
Excludes restricted cash. Percentages calculated by Merlintrader from reported amounts.
Source: Company Q2 2026 results / Form 10-Q; period ended June 30, 2026.
USD millions
External costs only; excludes personnel and overhead. Not total R&D expense.
Source: Company Q2 2026 results / Form 10-Q; period ended June 30, 2026.
Open the primary source for both charts
For the six months ended June 30, 2026, operating cash use was $168.582 million, equivalent to about $28.10 million per month by division by six. That historical average is not a forecast: working capital, trial spending and a new lupus program can change future use. Reported June liquidity of $502.3 million divided by that historical monthly rate corresponds to about 17.9 months from June 30, before future spending changes. Management’s current-plan guidance into Q4 2027 is a separate forward-looking assessment. The first-half net loss of $235.274 million also contains non-cash items, including $41.824 million of impairment and $26.612 million of equity compensation; net loss is therefore not the cash-burn measure. Q2 Form10-Q.
The share-count and liquidity statements have their own dates. A valuation must account for future development spending, equity compensation and any financing; the third-party market capitalization shown above is not an independently calculated enterprise value or the value of an approved product.
In January 2026 the company sold approximately 20.30 million shares at $17.00, generating about $345.1 million gross and $324.4 million net proceeds. In March it established an at-the-market program with up to $300 million of capacity; no shares had been sold under that program through June 30. The unused facility is financial flexibility and a dilution overhang, not evidence that a sale will occur.
Options, restricted stock units and other equity awards can expand the economic share base. A fully diluted valuation should use the latest footnote tables and option strike prices rather than the voting-share count alone. The sharp price decline also changes the efficiency and signaling cost of any future equity raise.
A disciplined sum-of-the-parts framework separates four components:
The market reaction implies a large reduction in lupus optionality and/or confidence in the asset platform. It does not reveal which component investors sold. A low price relative to the previous close is not itself evidence of undervaluation.
In plaque psoriasis, envudeucitinib must compete with highly effective injectable biologics, oral deucravacitinib, other oral systemics and a development pipeline of next-generation agents. Commercial differentiation may require a balance of deep skin clearance, durable response, convenient dosing, acceptable monitoring and payer access. A superior result in an indirect chart does not establish superiority.
In SLE, competitors include approved biologics directed at B-cell and interferon biology, background immunosuppressants and other oral pathway inhibitors in development. Alumis’ proposed advantage would be an oral therapy paired with a biologically selected population. Its disadvantage is that the selection hypothesis now carries the burden of rescuing an overall negative trial.
The approved deucravacitinib label also establishes a real regulatory and commercial TYK2 benchmark. Envudeucitinib may differ in dose, pharmacology, efficacy or safety, but those distinctions need comparative evidence and a final label before they become durable commercial claims.
A meeting request, planned submission or guided trial start becomes a confirmed event only when the company or regulator supplies a dated milestone.
LUMUS is a material clinical failure. The overall SLE population missed BICLA and the company says it missed the secondary endpoints; the adverse IFNGS-low pattern prevents a simple “good trial with the wrong mix” reading. The IFNGS-high signal is sufficiently coherent to justify a regulatory conversation because it was prespecified, dose-related on BICLA and supported by pharmacodynamics. It is not sufficiently proven to treat a Phase 3 as de-risked.
The investment debate now pivots back to psoriasis. ONWARD1, ONWARD2 and ONWARD3 provide a substantially stronger evidence package, and the Q4 2026 NDA target remains intact. Alumis also retains meaningful liquidity, but its loss and cash use show that the balance sheet is a runway, not a floor under the stock.
The honest question for ALMS: can a positive psoriasis registration package create enough value before the company must finance the next wave of development, while the lupus program proves—rather than assumes—that IFNGS enrichment works?
Source documents include the SEC-filed LUMUS release, the LUMUS data deck, the ClinicalTrials.gov record NCT05966480, Alumis’ Q2 2026 Form 10-Q and Q2 update, and the SEC-filed ONWARD1/2 topline, detailed Phase 3 data and ONWARD3 update. The current FDA SOTYKTU label is used only as a class benchmark, not as evidence about envudeucitinib. Market data are a dated secondary-source snapshot. Cross-trial comparisons are not head-to-head evidence.
LUMUS was a Phase 2b trial of envudeucitinib in 408 patients with moderate-to-severe autoantibody-positive systemic lupus erythematosus. It missed its primary endpoint, overall BICLA response at week 48. The company points to a signal in the subgroup of patients with a high interferon gene signature. A subgroup finding in a trial that missed its primary endpoint is a hypothesis to be tested prospectively, not a result.
Yes, and it is the part of the company the lupus miss did not touch. Envudeucitinib has two positive Phase 3 trials in plaque psoriasis with supportive 48-week extension data, and Alumis has guided a new drug application to the fourth quarter of 2026. The two programmes share a molecule but not an evidence package, and reading across from one to the other is the main way this company gets misjudged.
An oral allosteric TYK2 inhibitor, still investigational. Allosteric means it binds away from the enzyme’s active site, which is the design choice intended to give selectivity for TYK2 over the related JAK enzymes and therefore a different safety profile from the broader JAK inhibitors.
$502.3 million of cash, cash equivalents and marketable securities at June 30, 2026, as reported in the Form 10-Q filed on August 13, 2026, with a cash runway guided into the fourth quarter of 2027 on the company’s current operating plan. That plan predates any decision on a new lupus Phase 3 or a commercial build in psoriasis.
Two things, neither with a date. Whether the psoriasis new drug application is submitted inside the guided fourth-quarter 2026 window, and what the FDA and the EMA say at end-of-Phase-2 about running a lupus Phase 3 enriched for the interferon gene signature, including which dose and which assay would be acceptable. Alumis has not published timing for either.
Every Merlintrader stock hub, clinical update and verified catalyst change is published to Telegram. Join the discussion on the public community after reading the primary evidence.
Join @merlintraderpub_com on Telegram Visit r/MerlintraderPub
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent research, not investment advice, not a recommendation to buy, sell or hold any security, not an offer or solicitation, and not a personalised suitability assessment. Nothing here should be treated as a research report under applicable United States securities regulation. Readers should perform their own due diligence and consult an authorised financial adviser before making any decision.
Biotechnology securities can lose substantial or all value. A positive subgroup in an overall negative trial does not establish efficacy, regulatory acceptance or Phase 3 success. Positive Phase 3 results do not guarantee NDA acceptance, approval, commercial availability, reimbursement, adoption or sales. Trial results apply to the studied population, design, endpoints and follow-up.
Financial and market figures are dated and can change. Cash runway is issuer guidance, contingent milestones are not cash, and derived market capitalization or enterprise-like values are arithmetic rather than issuer guidance. Options, restricted stock units, the at-the-market facility and future financing may dilute common shareholders. Loss of principal is possible.
Merlintrader may hold positions in securities mentioned. Some links, including Finviz links, may be affiliate or referral links that can generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.
